Chapter 28: Concepts of Care for Patients With Infectious Respiratory Problems

Welcome to Last Minute Lecture.

This free chapter overview is designed to help students review and understand key concepts.

These summaries supplement not replaced the original textbook and may not be redistributed or resold.

For complete coverage, always consult the official text.

All right, welcome back to the Deep Dive.

Today we're really opening up the playbook on infectious respiratory problems.

Our goal here is to give you a solid clinical map, you know, pulling together everything from seasonal stuff right up to these bigger global challenges.

That's right.

And we're going to zero in on two really core concepts for managing these patients.

First up is gas exchange.

We'll look closely at pneumonia as our main example there.

And second is infection itself,

using pulmonary tuberculosis or TB to explore that sort of complex longer term picture.

And yeah, underpinning both of those are concepts you just have to keep in your head.

Immunity, obviously how the body fights back.

Inflammation, which is the response but often causes its own problems.

And maybe most importantly, for spotting trouble, early cognition, especially in vulnerable patients.

Definitely.

And before we jump in properly, maybe let's clarify a few terms, not just definitions, but what they mean clinically.

Like consolidation, you hear that a lot with pneumonia.

Right, sounds dense.

It is.

It's basically an abnormal solidification.

The air spaces in the lungs, they get filled up with inflammatory junk, exudate cells, fluid.

It's like the lung tissue turns spongy concrete almost.

Nowhere can get through.

Got it.

And then there's MPMA.

Yeah, that's a serious complication.

It's specifically when pus collects between the lung and the chest wall, in that plural space,

needs aggressive treatment, usually drainage.

Okay.

And one more really key concept for context,

pandemic infection.

This is crucial.

It refers to a situation, usually with a novel virus, where pretty much nobody has prior immunity, no ancestral immunity.

Meaning it can spread like wildfire globally.

Exactly.

That lack of baseline defense is what gives it that pandemic potential.

Okay.

So our plan for this deep dive is set.

We'll start with those fast moving viruses, flu, COVID -19 context, then we'll really dig into pneumonia and that gas exchange problem and wrap up with the long haul of tuberculosis.

Sound good.

Sounds like a plan.

All right, let's kick off with seasonal influenza.

We all know it.

Highly contagious, viral, hits you like tons of bricks, right?

Like sudden headache, muscle aches, fever, chills.

Yeah, the onset is rapid.

But the really critical piece for us clinically is the timing of when someone's contagious.

Ah, right.

It's kind of sneaky.

Adults can actually spread the virus a full 24 hours before they even feel sick.

Wow, a whole day.

A whole day.

And they can stay infectious for up to five days, sometimes longer after symptoms start.

That asymptomatic spread winter, that's why prevention is just so huge.

Which brings us to vaccination, annual shots.

And it's important to remember the vaccine changes each year, right?

Based on what strains are circulating.

Exactly.

And the source material specifically calls out the need for a higher dose version for adults over 65.

Their immune response can be a bit weaker, so they need that extra boost.

Makes sense.

Now, what if someone does get the flu treatment?

Well, the key is timing.

Those they work best if you start them super early.

How early?

Within 24 to 48 hours of symptoms starting.

That's the window.

If you start them then, they can really shorten how long you're sick and maybe how severe it gets.

Wait longer.

The virus has already replicated too much and the drug won't do nearly as much good.

That race against the clock feels very relevant when we think about pandemics like with COVID -19.

You mentioned these viruses jumping species, SARS, MERS, COVID.

Yeah.

And because humans had no prior immunity, we saw this enormous range of illness from people having zero symptoms to devastating viral pneumonia.

And COVID had some unique features beyond the usual fever and cough, didn't it?

That loss of taste or smell was distinctive.

It was.

But clinically, one of the most frightening things was the systemic impact,

particularly the prothrombotic state it could trigger.

Meaning blood clots.

Exactly.

The body's inflammatory response dramatically increased the risk of clots forming, leading to strokes, heart attacks, pulmonary emboli.

And we also saw significant neurological issues alongside the respiratory failure.

Which is why recognizing those emergency signs is so vital.

Trouble breathing, that persistent chest pain or pressure, any new confusion or that really scary sign,

bluish lips or face.

Cyanosis.

Yeah.

That signals severe hypoxemia.

That patient needs help immediately.

And that means immediate, strict infection control in the hospital.

Absolutely.

Standard precautions mean a single room, door closed.

But the game changes.

If you're doing anything that can create aerosols like suctioning, putting in a breathing tube, nebulizer treatments.

Right.

Then you need more.

Then you absolutely need an airborne infection isolation room and AIR if possible.

And the PPE goes up significantly.

We're talking a fitted N95 respirator, ideally with a face shield, plus gowns, shoe covers, gloves, goggles, full barrier protection.

You have to assume the air itself is contaminated.

That makes sense.

Okay, let's shift gears now to our gas exchange exemplar.

Pneumonia.

If viruses show a speed, pneumonia really demonstrates the damage from the body's own defenses going into overdrive.

That's a great way to put it.

The core issue is inflammation triggered by an infection.

Could be bacteria, viruses,

even fungi, or sometimes inhaled irritants.

So the body sends in the troops.

Right.

White blood cells flood the area.

But this causes the tiny blood vessels, the capillaries, to leak.

You get fluid buildup, edema, and all sorts of inflammatory debris that exudate, we mentioned.

And that's what causes the consolidation.

The solidifying of the lung tissue?

Exactly.

When that happens, the lung gets stiff, less compliant.

Air can't get in and out easily.

The tiny air sacs, the alveoli, can collapse.

That's atelectasis.

And the direct result is impaired gas exchange.

Hypoxemia.

And it can get worse, right?

Like sepsis.

Yes.

If those infectious organisms manage to break through the lung tissue and get into the bloodstream, that's sepsis or septicemia.

Right.

A systemic infection.

Or, as we mentioned, empyema, that collection of pus in the pleural space.

Both are major complications.

When we think about who's at risk, does it matter where they got the pneumonia?

It does.

The risk factors differ.

For community -acquired pneumonia,

CAP, meaning you caught it out in the community,

risks include things like older age, not getting vaccinated, having chronic health problems, smoking, heavy alcohol use.

But for healthcare -acquired pneumonia, HCAP, which includes ventilator -associated pneumonia or VAP, the risks are often related to being in the hospital or a long -term care facility itself.

Things like already having lung disease, being less conscious, having tubes like NG tubes or breathing tubes, or having a weakened immune system.

Now, let's talk assessment because there's a really critical point here, especially for older adults.

It's easy to miss.

This is so important.

We're trained to look for the classic signs.

Yeah.

Plus cheeks, maybe an anxious look, chest pain, definitely fever, cough, fast heart rate, shortness of breath.

The usual suspects.

Right.

But in an older adult, the fever and cough might be completely absent or very mild.

So what is the sign then?

The most common and often the first sign of pneumonia in an older person is a change in cognition.

Sudden confusion, maybe increased lethargy, new delirium.

It's often directly caused by the lack of oxygen, the hypoxia.

Wow.

So if you wait for a fever or a classic cough in an older patient, you could be dangerously delayed.

You could.

And that delay dramatically increases their risk of developing sepsis and having a much worse outcome.

So altered mental status in an older adult.

Think hypoxia, think infection, think pneumonia.

Okay.

That's a huge takeaway.

And if you listen to their lungs.

You'll likely hear crackles.

That's fluid popping open the small airways.

Breast sounds might be diminished in some areas, or you might hear bronchial breath sounds over the consolidated area, which isn't normal.

Tapping on the chest percussion will sound dull over that dense fluid filled tissue instead of resonant.

So how do we manage this?

What are the priorities?

Priority number one is always improving gas exchange.

Get that oxygen level up.

So oxygen therapy is key, tailored to their needs and aggressive bronchial hygiene, getting secretions up and out.

Which brings us to the incentive spirometer.

Yes.

But it has to be taught correctly.

It's not just blowing.

It's inhaling.

You tell the patient,

sit up straight, seal your lips around the mouthpiece.

Breathe in slowly and deeply.

Really feel your lungs.

And the hold.

Crucial.

Hold that breath for two to four seconds at the peak of inhalation.

That hold is what pops open those alveoli, prevents the atelectasis.

And they need to do this regularly.

Five to 10 good breaths every hour while they're awake.

Okay.

That makes sense.

Priority two.

Preventing airway obstruction.

Keep those airways clear.

So encourage coughing and deep breathing every couple of hours and push fluids at least two liters a day, unless they have a restriction like heart failure to help thin out those secretions so they're easier to cough up.

Sometimes bronchodilators or steroids are used to open airways and reduce inflammation.

And priority three must be fighting the infection itself.

Absolutely.

Preventing sepsis.

This means getting the right anti -infective on board.

For uncomplicated CAP, it might be five to seven days of antibiotics.

For HAP or more complex cases, it could be up to 21 days.

And you always have to consider local patterns of drug resistance, like drug resistance strep pneumo or DRSP.

It sounds like a coordinated effort really matters.

It does.

The text mentions a quality improvement example, the pneumonia recovery plan initiative.

By really standardizing care, focusing on patient and family education, and consistently applying evidence -based practice, they saw huge improvements.

Reduce length of stay and drop 30 -day readmissions way down from like 33 % to under 8%.

Wow.

That shows consistent nursing care really makes a difference system -wide.

It really does.

Okay.

Let's shift now to our infection exemplar.

Pulmonary tuberculosis.

TB.

This feels like a different kind of battle, right?

Slower, longer.

Very different.

It's a marathon, not a sprint.

And the focus shifts heavily towards adherence and honestly global public health safety.

First off, how does it spread?

Is it like the flu?

No.

And this is a key distinction.

TB caused by the bacterium mycobacterium tuberculosis spreads via the aerosolization route.

Tiny particles containing the bacteria hang suspended in the air after an infected person coughs, sneezes, speaks, or sings.

So it's truly airborne, not just droplets that fall quickly.

Exactly.

It can linger in the air.

That's why ventilation is so important in control.

And what happens once someone is infected?

What's the disease process?

Well, the body's immune system tries to fight back using cell -mediated immunity.

This usually kicks in about two to ten weeks after the initial infection.

The body tries to wall off the bacteria by forming these inflammatory structures called granulomas.

Inside these granulomas, the tissue can die off and turn into this cheesy granular material that's called caseation necrosis.

Now, if that material liquefies, it can actually spill out into a nearby airway, a bronchus, and create a hole or cavity in the lung.

That's cavitation.

And that cavity then allows the bacteria to spread more easily.

Precisely.

Both within the lungs and potentially to be coughed out, spreading the infection.

You often hear about latent TB versus active TB.

What's the difference?

It's critical.

Latent TB means the bacteria are present in the body, walled off by the immune system, but they're dormant.

The person isn't sick, has no symptoms, and importantly, cannot spread the disease to others.

Okay, so they're infected but not infectious.

Correct.

Secondary TB, or active TB, is when those dormant bacteria reactivate and start multiplying.

This often happens when the person's immune system becomes weakened for some reason, maybe due to aging, HIV infection, malnutrition, certain medications.

This is when they become sick and can spread the disease.

So who is most at risk for developing active TB or getting infected in the first place?

The highest risk groups are people in close contact with someone who has active TB.

Individuals with weakened immune systems, like those with HIV AIDS.

Also, people living or working in crowded settings, prisons, homeless shelters, some long -term care facilities.

Injection drug users and those with alcohol use disorder are also at higher risk, partly due to potential malnutrition and immune effects, and immigrants from parts of the world where TB is still very common.

How do you spot it?

The symptoms sound kind of vague and slow.

They are often slow and insidious, which makes diagnosis tricky sometimes.

We're looking for a persistent cough, often lasting three weeks or longer, maybe producing sputum, sometimes blood pinched.

Unintended weight loss is common, so is loss of appetite,

night sweats, drenching night sweats, fatigue, and a persistent low -grade fever.

How is it diagnosed then if the symptoms can be subtle?

The first step is often screening with a tuberculin skin test, the TST or MANTU test.

A small amount of purified protein derivative, PPD, is injected just under the skin.

And you read it a couple days later.

Right, 48 to 72 hours later.

And you're not measuring the redness, you're measuring the induration, the raised hardened swelling.

A reaction of 10 millimeters or more is generally considered positive for most people.

But smaller for some.

Yes, for people with significant immune compromise like HIV or recent close contacts or those with chest x -ray changes suggesting old TB,

a reaction of just five millimeters is considered positive.

What about false negatives?

That can happen.

It's called energy.

When someone's immune system is so suppressed, they don't mount a reaction to the skin test even if they are infected.

That's why you can't rely solely on the TST in very immunocompromised patients.

Are there other tests?

Blood tests?

Yes, the interferon gamma release assays or IG arrays.

Quantiferon TB Gold is a common one.

These are blood tests that are more specific than the skin test and aren't affected by prior BCG vaccination, which can cause a false positive TST.

Do they tell you if it's active disease?

No, like the TST, the IG arrays only tell you if the person have been infected with TB bacteria.

They can't distinguish between latent infection and active disease.

For that, you need more information.

Like a chest x -ray.

Exactly.

Yeah.

A chest x -ray can show signs of active TB disease like infiltrates or cavities, or it might show old healed lesions like calcified granulomas.

But the definitive diagnosis - It still comes from finding the bacteria itself.

A sputum culture for mycobacterium tuberculosis is the gold standard.

It confirms active disease.

And follow -up cultures are crucial to see if the treatment is working.

Usually they become negative after about three months of effective therapy.

Okay, let's talk treatment because this is where the drug resistance issue becomes huge.

It's the biggest challenge in TB control globally.

Because the bacteria can mutate and become easily,

you must treat active TB with multiple drugs simultaneously.

Combination therapy is mandatory.

What are the main drugs?

The first line drugs are the most effective and generally have fewer side effects.

The core four are isoniazid, INH, rifampin, RIF, pyrazinamide, PZA, and ethambutyl, EMB.

The initial phase of treatment usually involves all four of these for about eight weeks.

And it depends, but often it continues with INH and rifampin for another 18 weeks or longer.

The total duration is typically at least six months, so 26 weeks.

For drug resistant TB, like multi -drug resistant TB, MDR TB, or extensively drug resistant TB, XDR TB, treatment is much longer, often up to two years.

Uses second line drugs, which can be more toxic and less effective, and is far more complex.

And the key to preventing that resistance is?

Adherence.

Absolute complete adherence to the entire drug regimen for the full duration.

This is non -negotiable.

Skipping doses, stopping treatment early, that's exactly how drug resistance develops.

Non -adherence is the single biggest driver of MDR and XDR TB worldwide.

So patient education and support are critical.

What else do patients need to know?

Any major safety alerts?

Oh yes, a huge one.

Liver toxicity.

All the first line drugs can potentially damage the liver.

So patients must be taught to avoid all alcohol for the entire time they're on TB meds.

No beer, no wine, nothing.

It's crucial.

They also need to know the signs of liver problems, jaundice, dark urine, abdominal pain, and report them immediately.

Okay, no alcohol.

Anything else specific to the drugs?

Riff Impin has a very noticeable side effect.

It turns urine, sweat, tears, saliva, basically all body secretions in orange -reddish color.

It's harmless, but you have to warn patients about it beforehand, or they'll panic.

It can also permanently stain soft contact lenses, so they should wear glasses instead.

Good to know.

Given how critical adherence is, how do we actually ensure patients take all these pills for so long?

The gold standard strategy is Directly Observe Therapy, or DOT.

This literally means a health care worker, or sometimes a trained community member, watches the patient swallow every single dose of their medication.

Every dose.

That seems intense.

It is, but it's proven to be the most effective way to ensure completion of therapy and prevent resistance.

It also provides regular contact for support and monitoring side effects.

There are variations now, too, like video -T or video -DOT, where the observation happens remotely via smartphone.

So technology is helping there.

What about infection control for a hospitalized patient?

If a patient has suspected or confirmed active pulmonary TB,

they need to be placed on airborne precautions immediately.

This means a private room,

ideally an AIR with negative pressure ventilation.

Anyone entering the room must wear a fitted N95 respirator mask.

And how long do these precautions last?

Until the patient is confirmed to be non -infectious, which usually requires three consecutive sputum cultures collected on different days to be negative for TB bacteria.

And at home?

Once they go home, if they're still potentially infectious, they need education on covering their mouth and nose when coughing or sneezing, ensuring good ventilation in their home, and possibly wearing a standard surgical mask if they're going to be around crowds until their doctor says they're no longer contagious.

That covers TB really well.

Before we wrap up, you mentioned touching on a few other respiratory infections briefly, just for context.

Yeah, just quick differentiators.

Like rhinosinusitis, sinus infections.

Often starts non -infectiously, maybe allergies causing inflammation and blocking the sinus openings.

And that blockage traps mucus.

Exactly.

Creates a perfect breeding ground for bacteria.

So what started as inflammation can become a bacterial infection requiring antibiotics.

Management initially focuses on decongestants, humidity,

maybe nasal steroids to reduce inflammation and promote drainage.

Okay.

What about peritonsillar abscess?

You said that was serious.

It is.

It's a complication of tonsillitis, basically the collection of pus behind the tonsil.

It's rare, but dangerous because it can rapidly swell and block the airway.

What are the red flags?

Severe, usually one -sided throat pain, muffled voice, sometimes called a hot potato voice, difficulty swallowing, maybe drooling.

And you might see the uvula, little thing hanging in the back, pushed over to the unaffected side by the swelling.

That's an airway emergency.

Good to know.

And you mentioned anthrax, inhalation anthrax.

Yes.

Mainly in the context of bioterrorism, though it can occur naturally rarely.

It's caused by inhaling spores of bacillus anthracis.

Importantly, it's not spread from person to person.

What does it look like?

It has two stages.

The first or prodromal stage looks like the flu fever, fatigue, muscle aches, but typically without the usual runny nose with sore throat.

If it's caught and treated with antibiotics here, survival is much higher.

And the second stage.

That's the fulminant stage, sudden severe respiratory distress, shortness of breath, shock, often bleeding in the chest cavity.

It progresses incredibly rapidly.

And even with aggressive treatment, mortality is very high, often within 24 to 36 hours.

If you suspect inhalation anthrax from a non -occupational exposure, it's an immediate public health emergency and needs reporting.

Okay.

And lastly, those geographic infections.

Right.

Things like cochidiotomycosis, valley fever in the southwest US, or histoplasmosis in the Ohio River Valley.

These are often fungal spores inhaled from the environment.

They can cause flu -like or pneumonia -like symptoms.

The key is they are not contagious person to person, and diagnosis requires knowing the patient's travel history or where they live.

Always ask about geography.

Excellent points.

Okay.

Let's try and bring this all together.

We've covered a lot of ground.

We have.

We started with those acute viral threats, influenza, and the pandemic contacts like COVID -19, really emphasizing that early contagion period, the need for rapid antiviral treatment, and strict PPE, especially N95s for aerosol risks.

Then we dove into pneumonia, our gas exchange exemplar.

We saw how inflammation leads to consolidation, blocking oxygen transfer.

And we hit that critical point about recognizing confusion, not just fever or cough, as a primary sign of hypoxia in older adults.

And finally, tuberculosis.

The long game.

We stress the airborne transmission route, the process of caseation and cavitation, the absolute necessity of combination drug therapy, and the societal importance of adherence through methods like DOT or VDOT to prevent MDR and XDRTD.

Don't forget the alcohol warning and the refamp and color change.

It really highlights the spectrum from rapid viruses to chronic bacterial infections and the different nursing priorities for each.

The consistent themes seem to be vigilance and assessment, strict infection control, and powerful patient education.

Absolutely.

Especially with TB,

that patient education and support around adherence isn't just about that one patient.

It directly impacts community and global health by preventing the level of prevention in that context.

So building on that, let's leave you, our listener, with a provocative thought to mull over.

If non -adherence to anti -infective, particularly for TD, is such a major driver of global drug resistance, what truly radical new strategies going beyond just watching someone swallow a pill with DOT could the entire health care team develop?

How can we better leverage true patient partnership to tackle this threat and prevent that next wave of potentially untreatable infections?

Tell them to think about.

Thank you for joining us for this deep dive into these critical infectious respiratory concepts.

We really appreciate you tuning in.

We'll catch you on the next one.